KC
BIVI icon

Kepos Capital’s BioVie BIVI Stock Holding History

Kepos Capital’s Portfolio BIVI Stock Details BIVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-250
Closed -$36K – 499
2022
Q2 		$36K Sell
250
-5,400
-96% -$1.62M ﹤0.01% 365
2022
Q1 		$2.67M Sell
5,650
-600
-10% -$222K 0.2% 152
2021
Q4 		$2.81M Hold
6,250
– – 0.23% 162
2021
Q3 		$4.18M Buy
+6,250
New +$6.7M 0.28% 166

Other funds holding BIVI

S
swisspartners Vaduz, Liechtenstein $78.4M AUM 9.82% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Kepos Capital's BIVI Position: Q3 2022 in Review

Kepos Capital sold out of BioVie (BIVI) in Q3 2022, closing a stake of 250 shares — an estimated $36K sold.

Kepos Capital first reported a position in BIVI in Q3 2021 and held it in 4 quarters. The position peaked at $4.18M in Q3 2021. 18 funds tracked by Wall St. Rank hold BIVI as of Q3 2022.

  • Kepos Capital reported no remaining BioVie position as of Q3 2022 after selling out during the quarter.
  • Kepos Capital sold 250 BioVie shares in Q3 2022, an estimated $36K.
  • Kepos Capital first reported a position in BioVie in Q3 2021 and held it in 4 quarters.
  • Kepos Capital's BioVie position peaked at $4.18M in Q3 2021.
  • 18 funds tracked by Wall St. Rank held BioVie as of Q3 2022.

Based on Kepos Capital's 13F filing for Q3 2022, filed 14 Nov 2022.